Deepak P. Chandrasekharan

Deepak P. Chandrasekharan

Auto-generated profile, based on publicly available information

Deepak P. Chandrasekharan

Lungs for Living Research Centre, UCL Respiratory, University College London, London, UK

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
VTVitor H. Teixeira
Vitor H. Teixeira
CPChristodoulos P. Pipinikas
Christodoulos P. Pipinikas
APAdam Pennycuick
Adam Pennycuick
HLHenry Lee-Six
Henry Lee-Six
DCDeepak Chandrasekharan
Deepak Chandrasekharan
SJSam M. Janes
Sam M. Janes

1 October 2020 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
APAdam Pennycuick
Adam Pennycuick
VTVitor H. Teixeira
Vitor H. Teixeira
KAKhalid AbdulJabbar
Khalid AbdulJabbar
SAShan E Ahmed
Shan E Ahmed
TLTom Lund
Tom Lund
SJSam M. Janes
Sam M. Janes
Before squamous cell lung cancer develops, precancerous lesions can be found in the airways. From longitudinal monitoring, we know that only half of such lesions become cancer, whereas a third spontaneously regress. Although recent studies have described the presence of an active immune response in high-grade lesions, the mechanisms underpinning clinical regression of precancerous lesions remain unknown. Here, we show that host immune surveillance is strongly implicated in lesion regression. Using bronchoscopic biopsies from human subjects, we find that regressive carcinoma in situ lesions harbor more infiltrating immune cells than those that progress to cancer. Moreover, molecular profiling of these lesions identifies potential immune escape mechanisms specifically in those that progress to cancer: antigen presentation is impaired by genomic and epigenetic changes, CCL27–CCR10 signaling is upregulated, and the immunomodulator TNFSF9 is downregulated. Changes appear intrinsic to the carcinoma in situ lesions, as the adjacent stroma of progressive and regressive lesions are transcriptomically similar. Significance: Immune evasion is a hallmark of cancer. For the first time, this study identifies mechanisms by which precancerous lesions evade immune detection during the earliest stages of carcinogenesis and forms a basis for new therapeutic strategies that treat or prevent early-stage lung cancer. See related commentary by Krysan et al., p. 1442. This article is highlighted in the In This Issue feature, p. 1426

31 May 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
RHRobert E. Hynds
Robert E. Hynds
AHAriana Huebner
Ariana Huebner
DPDavid R. Pearce
David R. Pearce
MHMark S. Hill
Mark S. Hill
AAAyse U. Akarca
Ayse U. Akarca
CSCharles Swanton
Charles Swanton
Patient-derived xenograft (PDX) models are widely used in cancer research. To investigate the genomic fidelity of non-small cell lung cancer PDX models, we established 48 PDX models from 22 patients enrolled in the TRACERx study. Multi-region tumor sampling increased successful PDX engraftment and most models were histologically similar to their parent tumor. Whole-exome sequencing enabled comparison of tumors and PDX models and we provide an adapted mouse reference genome for improved removal of NOD scid gamma (NSG) mouse-derived reads from sequencing data. PDX model establishment caused a genomic bottleneck, with models often representing a single tumor subclone. While distinct tumor subclones were represented in independent models from the same tumor, individual PDX models did not fully recapitulate intratumor heterogeneity. On-going genomic evolution in mice contributed modestly to the genomic distance between tumors and PDX models. Our study highlights the importance of considering primary tumor heterogeneity when using PDX models and emphasizes the benefit of comprehensive tumor sampling.


3 April 2023
Verified
Other
Open access
APAdam Pennycuick
Adam Pennycuick
VTVitor H. Teixeira
Vitor H. Teixeira
KAKhalid AbdulJabbar
Khalid AbdulJabbar
SAShan E Ahmed
Shan E Ahmed
TLTom Lund
Tom Lund
SJSam M. Janes
Sam M. Janes
Details of molecular investigations performed on each sample. Clinical and outcome data is also presented. In all cases with a previous history of lung cancer, this was of squamous histology.